Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified
monophosphate prodrug of remdesivir parent nucleoside (GS-441524)

Michael K. Lo^{a*} #, Punya Shrivastava-Ranjan^a, Payel Chatterjee^a, Mike Flint^a, James R. Beadle^b, Nadejda
Valiaeva^b, Robert T. Schooley^b, Karl Y. Hostetler^b, Joel M. Montgomery^a, and Christina Spiropoulou^{a*}

^aViral Special Pathogens Branch, Centers for Disease Control and Prevention, Department of Health and
Human Services, Atlanta, Georgia, USA

^bDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of
California San Diego, La Jolla, California, USA

Running title: Antiviral potency of lipid-modified remdesivir nucleoside

*Address correspondence to:

#Michael K. Lo: mko2@cdc.gov and Christina F. Spiropoulou: ccs8@cdc.gov

KEYWORDS: SARS-CoV-2, Ebola virus, Nipah virus, respiratory viruses, hemorrhagic fever virus, filovirus,
paramyxovirus, henipavirus, Remdesivir, GS-5734, Remdesivir nucleoside, GS-441524, antiviral agents,
lipid prodrugs, ODBG, Vero E6 cells, Huh7 cells, NCI-H358 cells, human telomerase reverse-transcriptase
(hTERT) immortalized microvascular endothelial cells (TIME), and human small airway epithelial cells
(HSAEC1-KT)

ABSTRACT

The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2. ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524 and had near-equivalent activity to remdesivir in primary-like human small airway epithelial cells. Our results warrant investigation of ODBG-P-RVn efficacy in vivo.

Remdesivir (RDV; Veklury, GS-5734) is an adenosine nucleotide analog phosphoramidate prodrug with broad-spectrum antiviral activity in vitro and in vivo (1-8), and is currently the only therapeutic approved by the FDA for treating coronavirus 19 disease (COVID-19) in hospitalized patients over the age of 12 (9). While RDV did not significantly reduce COVID-19 mortality, it did shorten the time to recovery compared to a placebo control group (10). The short half-life of RDV in human and animal plasma (1, 8, 11, 12), alongside the in vivo efficacy of RDV parent nucleoside (GS-441524, RVn) against coronaviruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (13-16), have driven proposals to utilize RVn instead of RDV to treat COVID-19 (17). A recent comparative pharmacokinetic study in non-human primates, however, demonstrated higher nucleoside triphosphate (NTP) levels in lower respiratory tract tissues of RDV-dosed animals than in RVn-dosed animals (8). A significant drawback of RDV is the requirement for intravenous administration, which limits its use to hospital contexts. In an attempt to develop an orally bioavailable form of remdesivir, we recently synthesized a 1-O-octadecyl-2-O-benzyl-sn-glycerylester (ODBG) lipid-modified monophosphate prodrug of RVn (ODBG-P-RVn), which demonstrated more favorable in vitro antiviral activity against SARS-CoV-2 compared to that of RVn and RDV in Vero-E6 cells (18).

In this study, we extended our in vitro comparisons to include 14 viruses from across 7 virus families responsible for causing diseases of significant human public health concern. These were *Filoviridae*: Ebola virus (EBOV) and Marburg virus (MARV) (19, 20); *Paramyxoviridae*: Nipah virus (NiV), Hendra virus (HeV), human parainfluenza virus 3 (hPIV3), measles virus (MV), mumps virus (MuV), and Sosuga virus (SoSuV) (21-27); *Pneumoviridae*: respiratory syncytial virus (RSV) (28); *Flaviviridae*: yellow fever virus (YFV); *Arenaviridae*: Lassa virus (LASV) (29); *Nairoviridae*: Crimean-Congo hemorrhagic fever virus (CCHFV) (30); and *Coronaviridae*: SARS-CoV-2 (31). We utilized 3 previously described assays to compare the antiviral activities of RVn, RDV, and ODBG-P-RVn against this panel of viruses: 1) directly measuring fluorescence of a reporter protein expressed by recombinant viruses (REP) (2), (Figure 1A); 2)

quantitating focus-forming units (FFU) via fluorescent reporter imaging (32) (Figure 1B); and 3) indirectly measuring cytopathic effect (CPE) based on cellular ATP levels (CellTiterGlo 2.0, Promega) (2) (Figure 1C), which was also used to evaluate compound cytotoxicity (Figure 1D). Assay conditions varied based on virus replication kinetics and on the specific assay used; multiplicities of infection (MOI) ranged from 0.01–0.25, and endpoint measurements were conducted between 72–144 hours post-infection (hpi). We initially conducted dose-response experiments using 8-point, 3-fold serial dilutions of RVn, RDV, and ODBG-P-RVn against our panel of viruses in Vero-E6 cells, and showed that ODBG-P-RVn consistently had greater antiviral activity than RVn and RDV against all viruses susceptible to RVn/RDV inhibition, with effective concentration (EC_{50}) values ranging from 0.026 to 1.13 μ M (Figure 1, Vero-E6 assays represented in left column of panels A, B, C; Supplemental Figure S1; Table 1). RVn and ODBG-P-RVn induced partial cytotoxicity but only at the highest concentration tested (100 μ M) and without reaching 50% cytotoxicity (CC_{50}). We then compared these antivirals in human hepatoma (Huh7) and bronchioalveolar carcinoma (NCI-H358) cell lines, which represent more relevant cell types targeted by subsets of viruses used in our study. In both human cell lines, although ODBG-P-RVn showed EC_{50} values remarkably similar to those observed in Vero-E6 cells and was 3- to 5-fold more active than RVn, it consistently showed 6- to 20-fold less activity than RDV (Figure 1 [Huh7 and NCI-H358 assays represented, respectively, in the middle and right columns of panels A, B, and C]; Supplemental Figures S2, S3; Table 1). Whereas CC_{50} values for RDV in Huh7 and NCI-H358 cells were 54.2 and 77.2 μ M, respectively, ODBG-P-RVn was less cytotoxic in Huh7 cells (CC_{50} = 93.4 μ M) and did not show measurable cytotoxicity in NCI-H358 cells even at the highest concentration tested (100 μ M) (Figure 1D, right panel; Table 1).

To further evaluate cell type-specific effects on the antiviral activities of RVn, RDV, and ODBG-P-RVn, we tested them against a smaller subset of filoviruses (EBOV-ZsG, MARV-ZsG) and a paramyxovirus (NiV-ZsG) expressing ZsGreen reporter in primary-like human telomerase reverse transcriptase (hTERT)

immortalized human microvascular endothelial (TIME) cells (33, 34). In TIME cells, we observed a similar trend in antiviral activity as in Huh7 and NCI-H358 cells, with ODBG-P-RVn showing 15- to 22-fold greater activity than RVn, but 5- to 8-fold less activity than RDV in reporter-based assays (Figure 2A, Table 2). To confirm this, we compared the respective abilities of RDV and ODBG-P-RVn to reduce infectious yield of EBOV-ZsG and NiV-ZsG (MOI = 0.25) when cells were treated with each compound 2 hpi. Virus supernatants were collected at 72hpi and titered on Huh7 (for EBOV-ZsG) or NCI-H358 (for NiV-ZsG) cells to determine 50% tissue culture infectious dose (TCID₅₀) by the method of Reed and Muench (35). Both RDV and ODBG-P-RVn equivalently reduced infectious yield of EBOV-ZsG by up to 4 log₁₀ and of NiV-ZsG by approximately 2 log₁₀, in a dose-dependent manner, with EC₅₀ values closely mirroring values determined in reporter assays (Figure 2B, left and middle panels; Table 2). However, RDV was more cytotoxic (CC₅₀ = 17.2 μM) than ODBG-P-RVn (CC₅₀ > 50 μM) (Figure 2B, right panel; Table 2), which is reflected in its biphasic inhibition of NiV-ZsG (Figure 2B, middle panel, cytotoxic inhibition by RDV shown at 16.6 μM). Since the ODBG lipid modification has been shown to enhance in vivo lung tissue distribution for a different orally administered nucleoside (36), we compared the activity of the 3 compounds against filoviruses, paramyxoviruses, and RSV in another primary-like, hTERT-immortalized small airway epithelial cell (HSAEC1-KT) (37). Notably, the dose-response curves of RDV and ODBG-P-RVn were strikingly similar, with EC₅₀ values in the submicromolar range within a 3-fold range of each other; EC₅₀ values for some viruses were almost identical (Figure 2C; Supplemental Figure 4; Table 2). Furthermore, RDV and ODBG-P-RVn equivalently reduced the infectious yields of EBOV-ZsG and NiV-ZsG in HSAEC1-KT cells by 5 log₁₀ and 3 log₁₀, respectively, and their EC₅₀ values reflected the limited differential in antiviral activity between them (Figure 2D, left and middle panels; Table 2). Although ODBG-P-RVn was more cytotoxic (CC₅₀ = 20.5) in HSAEC1-KT cells than RDV (CC₅₀ > 100; Figure 2D, right panel; Table 2), it also effectively reduced virus yields at non-cytotoxic concentrations.

In summary, our results demonstrate that ODBG-P-RVn has greater antiviral activity than RVn in all cell lines tested and has cell-type dependent activity levels that range from moderately lesser than to nearly equal to those of RDV. *In vivo* RDV is converted rapidly to RVn (1, 8, 11, 12), which has 0.5 to 2 log₁₀ less activity than RDV against most of the viruses tested. In contrast, ODBG-P-RVn is stable in plasma for >24 hours and at therapeutic plasma levels of ODBG-P-Rvn (above EC₉₀ for SARS-CoV-2) after oral administration of 16.9 mg/kg to Syrian hamsters; furthermore RVn was not observed at virologically significant levels (38). Thus, one would predict sustained *in vivo* antiviral activity with ODBG-P-RVn without substantial generation in plasma of RVn, the less active metabolite. Taken together, our results strongly support investigation of *in vivo* efficacy of ODBG-P-RVn not only against SARS-CoV-2 but also against other viruses significant to human health.

ACKNOWLEDGMENTS

We thank Tatyana Klimova for helpful comments in reviewing the manuscript. We thank Pei-Yong Shi (University of Texas Medical Branch) for the kind gift of the reporter SARS-CoV-2 expressing mNeonGreen. The findings and conclusions in this report are those of the authors and do not necessarily represent those of the Centers for Disease Control and Prevention. This work was supported by CDC core funding and by the National Institute of Allergy and Infectious Diseases (RO1-AI131424).

References

1. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, et al. 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature* 531:381-5.
2. Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, Flint M, McMullan LK, Siegel D, Clarke MO, Mackman RL, Hui HC, Perron M, Ray AS, Cihlar T, Nichol ST, Spiropoulou CF. 2017. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. *Sci Rep* 7:43395.
3. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. 2017. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Sci Transl Med* 9.
4. Lo MK, Feldmann F, Gary JM, Jordan R, Bannister R, Cronin J, Patel NR, Klena JD, Nichol ST, Cihlar T, Zaki SR, Feldmann H, Spiropoulou CF, de Wit E. 2019. Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge. *Sci Transl Med* 11.
5. de Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, Scott D, Cihlar T, Feldmann H. 2020. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *Proc Natl Acad Sci U S A* doi:10.1073/pnas.1922083117.
6. Pruijssers AJ, George AS, Schafer A, Leist SR, Gralinski LE, Dinnon KH, 3rd, Yount BL, Agostini ML, Stevens LJ, Chappell JD, Lu X, Hughes TM, Gully K, Martinez DR, Brown AJ, Graham RL, Perry JK, Du Pont V, Pitts J, Ma B, Babusis D, Murakami E, Feng JY, Bilello JP, Porter DP, Cihlar T, Baric RS, Denison MR, Sheahan TP. 2020. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. *Cell Rep* 32:107940.
7. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE, Bauer L, Sellers S, Porter D, Feng JY, Cihlar T, Jordan R, Denison MR, Baric RS. 2020. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. *Nat Commun* 11:222.
8. Mackman RL, Hui HC, Perron M, Murakami E, Palmiotti C, Lee G, Stray K, Zhang L, Goyal B, Chun K, Byun D, Siegel D, Simonovich S, Du Pont V, Pitts J, Babusis D, Vijapurapu A, Lu X, Kim C, Zhao X, Chan J, Ma B, Lye D, Vandersteen A, Wortman S, Barrett KT, Toteva M, Jordan R, Subramanian R, Bilello JP, Cihlar T. 2021. Prodrugs of a 1 β -CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV. *Journal of Medicinal Chemistry* 64:5001-5017.
9. Gilead. 2020. <https://www.veklury.com/>. Accessed 07/08/2021.
10. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh M-d, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC. 2020. Remdesivir for the Treatment of Covid-19 — Final Report. *New England Journal of Medicine* 383:1813-1826.

11. Tempestilli M, Caputi P, Avataneo V, Notari S, Forini O, Scorzolini L, Marchioni L, Ascoli Bartoli T, Castilletti C, Lalle E, Capobianchi MR, Nicastri E, D'Avolio A, Ippolito G, Agrati C, Group CIS. 2020. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. *J Antimicrob Chemother* 75:2977-2980.
12. Humeniuk R, Mathias A, Cao H, Osinusi A, Shen G, Chng E, Ling J, Vu A, German P. 2020. Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects. *Clin Transl Sci* 13:896-906.
13. Shi Y, Shuai L, Wen Z, Wang C, Yan Y, Jiao Z, Guo F, Fu ZF, Chen H, Bu Z, Peng G. 2021. The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract. *Emerging Microbes & Infections* 10:481-492.
14. Li Y, Cao L, Li G, Cong F, Li Y, Sun J, Luo Y, Chen G, Li G, Wang P, Xing F, Ji Y, Zhao J, Zhang Y, Guo D, Zhang X. 2021. Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models. *J Med Chem* doi:10.1021/acs.jmedchem.0c01929.
15. Murphy BG, Perron M, Murakami E, Bauer K, Park Y, Eckstrand C, Liepnieks M, Pedersen NC. 2018. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. *Vet Microbiol* 219:226-233.
16. Pedersen NC, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M, Liu H. 2019. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. *J Feline Med Surg* 21:271-281.
17. Yan VM, F. 2020. Comprehensive Summary Supporting Clinical Investigation of GS-441524 for Covid-19 Treatment. doi:10.31219, OSFPREPRINTS.
18. Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang XQ, Garretson AF, Smith VI, Murphy J, Hostetler KY. 2020. Rethinking Remdesivir: Synthesis of Lipid Prodrugs that Substantially Enhance Anti-Coronavirus Activity. *bioRxiv* doi:10.1101/2020.08.26.269159.
19. Albarino CG, Wiggleton Guerrero L, Lo MK, Nichol ST, Towner JS. 2015. Development of a reverse genetics system to generate a recombinant Ebola virus Makona expressing a green fluorescent protein. *Virology* 484:259-64.
20. Lo MK, Jordan PC, Stevens S, Tam Y, Deval J, Nichol ST, Spiropoulou CF. 2018. Susceptibility of paramyxoviruses and filoviruses to inhibition by 2'-monofluoro- and 2'-difluoro-4'-azidocytidine analogs. *Antiviral Res* 153:101-113.
21. Zhang L, Bukreyev A, Thompson CI, Watson B, Peeples ME, Collins PL, Pickles RJ. 2005. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. *J Virol* 79:1113-24.
22. Lo MK, Nichol ST, Spiropoulou CF. 2014. Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screening. *Antiviral Res* 106:53-60.
23. Rennick LJ, de Vries RD, Carsillo TJ, Lemon K, van Amerongen G, Ludlow M, Nguyen DT, Yuksel S, Verburgh RJ, Haddock P, McQuaid S, Duprex WP, de Swart RL. 2015. Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates. *J Virol* 89:2192-200.
24. Xu P, Li Z, Sun D, Lin Y, Wu J, Rota PA, He B. 2011. Rescue of wild-type mumps virus from a strain associated with recent outbreaks helps to define the role of the SH ORF in the pathogenesis of mumps virus. *Virology* 417:126-136.
25. Welch SR, Chakrabarti AK, Wiggleton Guerrero L, Jenks HM, Lo MK, Nichol ST, Spiropoulou CF, Albariño CG. 2018. Development of a reverse genetics system for Sosuga virus allows rapid screening of antiviral compounds. *PLoS neglected tropical diseases* 12:e0006326-e0006326.

26. Murray K, Selleck P, Hooper P, Hyatt A, Gould A, Gleeson L, Westbury H, Hiley L, Selvey L, Rodwell B, et al. 1995. A morbillivirus that caused fatal disease in horses and humans. *Science* 268:94-7.
27. Harcourt BH, Lowe L, Tamin A, Liu X, Bankamp B, Bowden N, Rollin PE, Comer JA, Ksiazek TG, Hossain MJ, Gurley ES, Breiman RF, Bellini WJ, Rota PA. 2005. Genetic characterization of Nipah virus, Bangladesh, 2004. *Emerg Infect Dis* 11:1594-7.
28. Hallak LK, Spillmann D, Collins PL, Peeples ME. 2000. Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. *J Virol* 74:10508-13.
29. Welch SR, Guerrero LW, Chakrabarti AK, McMullan LK, Flint M, Bluemling GR, Painter GR, Nichol ST, Spiropoulou CF, Albarino CG. 2016. Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems. *Antiviral Res* 136:9-18.
30. Welch SR, Scholte FEM, Flint M, Chatterjee P, Nichol ST, Bergeron É, Spiropoulou CF. 2017. Identification of 2'-deoxy-2'-fluorocytidine as a potent inhibitor of Crimean-Congo hemorrhagic fever virus replication using a recombinant fluorescent reporter virus. *Antiviral Research* 147:91-99.
31. Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, Liu J, Schindewolf C, Bopp NE, Aguilar PV, Plante KS, Weaver SC, Makino S, LeDuc JW, Menachery VD, Shi PY. 2020. An Infectious cDNA Clone of SARS-CoV-2. *Cell Host Microbe* 27:841-848.e3.
32. Lo MK, Amblard F, Flint M, Chatterjee P, Kasthuri M, Li C, Russell O, Verma K, Bassit L, Schinazi RF, Nichol ST, Spiropoulou CF. 2020. Potent in vitro activity of β -D-4-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus. *Antiviral Research* 175:104712.
33. Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, Neville S, Carra E, Lew W, Ross B, Wang Q, Wolfe L, Jordan R, Soloveva V, Knox J, Perry J, Perron M, Stray KM, Barauskas O, Feng JY, Xu Y, Lee G, Rheingold AL, Ray AS, Bannister R, Strickley R, Swaminathan S, Lee WA, Bavari S, Cihlar T, Lo MK, Warren TK, Mackman RL. 2017. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. *J Med Chem* 60:1648-1661.
34. Venetsanakos E, Mirza A, Fanton C, Romanov SR, Tlsty T, McMahon M. 2002. Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells. *Exp Cell Res* 273:21-33.
35. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. *Am J Hygiene* 27:493-497.
36. Hostetler KY, Beadle JR, Trahan J, Aldern KA, Owens G, Schriewer J, Melman L, Buller RM. 2007. Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice. *Antiviral Res* 73:212-8.
37. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM, Milchgrub S, Smith AL, Souza RF, Gilbey L, Zhang X, Gandia K, Vaughan MB, Wright WE, Gazdar AF, Shay JW, Minna JD. 2004. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. *Cancer Res* 64:9027-34.
38. Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang X-Q, Clark AE, McMillan RE, Leibel SL, McVicar RN, Xie J, Garretson AF, Smith VI, Murphy J, Hostetler KY. 2021. Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs. *Antimicrobial Agents and Chemotherapy* 0:AAC.01155-21.

FIGURE LEGENDS

Figure 1. Comparison of antiviral activities of RVn, RDV, and ODBG-P-RVn in African green monkey (Vero-E6), human hepatoma (Huh7), and human bronchioalveolar carcinoma (NCI-H358) cell lines using reporter-based, image-based, and cytopathic effect (CPE) assays. Representative dose-response inhibition of viral replication and induction of cellular cytotoxicity by RVn (blue shapes), RDV (black shapes), and ODBG-P-RVn (red shapes). A) Direct measurement of reporter fluorescence intensity by recombinant Ebola virus (EBOV) expressing ZsGreen protein in Vero-E6 (left panel) and Huh7 (middle panel) cells, and recombinant Nipah virus (NiV) expressing ZsGreen protein in NCI-H358 (right panel) cells. B) Image-based counting of reporter fluorescence-positive cells infected with recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) expressing mNeonGreen protein (Vero-E6 and Huh7) and recombinant respiratory syncytial virus (RSV) expressing eGFP (NCI-H358). Infected cells treated with DMSO were considered as 100% fluorescence intensity signal and 100% fluorescence-positive cell counts. C) Compound-based inhibition of CPE induced by yellow fever virus (YFV) in Vero-E6 and Huh7 cells and by Hendra virus (HeV) in NCI-H358 cells determined by measuring cellular ATP levels (CellTiterGlo 2.0). ATP levels in uninfected cells treated with DMSO were considered 100% CPE inhibition. D) Compound cytotoxicity/cell viability measured by CellTiterGlo 2.0 assay. Dose-response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point, 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 biological replicates; each colored shape/line in the legend represents an independent experiment performed in biological triplicate. RVn and RDV used in this study was obtained from MedChemExpress (Monmouth Junction, NJ USA).

Figure 2. Comparison of cell type-dependent antiviral activities of RVn, RDV, and ODBG-P-RVn in primary-like hTERT-immortalized microvascular endothelial (TIME) cells and small airway epithelial cells

(HSAEC1-KT). A) Representative dose-response inhibition of recombinant EBOV, NiV, and Marburg virus (MARV) expressing ZsGreen protein in TIME cells. B) Yield reduction of infectious EBOV-ZsG (left panel) and NiV-ZsG (middle panel) by RDV and ODBG-P-RVn. Compound cytotoxicity/cell viability (right panel) in TIME cells measured via CellTiterGlo 2.0 assay. C) Representative dose-response inhibition of recombinant EBOV, NiV, and MARV expressing ZsGreen protein in HSAEC1-KT cells. D) Reduction of infectious yield of EBOV-ZsG (left panel) and NiV-ZsG (middle panel) by RDV and ODBG-P-RVn in HSAEC1-KT cells. Compound cytotoxicity/cell viability (right panel) in HSAEC1-KT cells measured via CellTiterGlo 2.0 assay. Dose-response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point, 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 or 4 biological replicates; each colored shape/line in the legend represents an independent experiment performed in biological triplicate. Infectious yield reduction assays were conducted once with biological quadruplicates.

SUPPLEMENTAL FIGURE LEGENDS

Supplemental Figure S1. Comparison of antiviral activities of RVn, RDV, and ODBG-P-RVn in African green monkey (Vero-E6) cells using reporter-based, image-based, and CPE assays. Representative dose-response inhibition of virus replication by RVn (blue shapes), RDV (black shapes), and ODBG-P-RVn (red shapes). Signal from infected cells treated with DMSO served as 100% fluorescence intensity signal for reporter assays and 100% fluorescence-positive cell counts for image-based assays. CPE inhibition was measured by determining cellular ATP levels using CellTiterGlo 2.0 assay reagent. ATP levels in uninfected cells treated with DMSO served as 100% CPE inhibition. Dose-response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point, 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 biological replicates; each

colored shape/line in the legend represents an independent experiment performed in biological triplicate.

Supplemental Figure S2. Comparison of antiviral activities of RVn, RDV, and ODBG-P-RVn in Huh7 cells using reporter-based, image-based, and CPE assays. Representative dose-response inhibition of virus replication by RVn (blue shapes), RDV (black shapes), and ODBG-P-RVn (red shapes). Signal from infected cells treated with DMSO served as 100% fluorescence intensity signal for reporter assays and 100% fluorescence-positive cell counts for image-based assays. CPE inhibition was measured by determining cellular ATP levels using CellTiterGlo 2.0 assay reagent. ATP levels in uninfected cells treated with DMSO served as 100% CPE inhibition. Dose-response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point, 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 biological replicates; each colored shape/line in the legend represents an independent experiment performed in biological triplicate.

Supplemental Figure S3. Comparison of antiviral activities of RVn, RDV, and ODBG-P-RVn in human bronchioalveolar carcinoma (NCI-H358) cells using reporter-based, image-based, and CPE assays. Representative dose-response inhibition of virus replication by RVn (blue shapes), RDV (black shapes), and ODBG-P-RVn (red shapes). Signal in infected cells treated with DMSO served as 100% fluorescence intensity signal for reporter assays and 100% fluorescence-positive cell counts for image-based assays. CPE inhibition was measured by determining cellular ATP levels using CellTiterGlo 2.0 assay reagent. ATP levels in uninfected cells treated with DMSO served as 100% CPE inhibition. Dose-response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point, 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 biological

replicates; each colored shape/line in the legend represents an independent experiment performed in biological triplicate.

Supplemental Figure S4. Comparison of antiviral activities of RVn, RDV, and ODBG-P-RVn in primary-like human small airway epithelial (HSAEC1-KT) cells using reporter-based, image-based, and CPE assays.

Representative dose-response inhibition of virus replication by RVn (blue shapes), RDV (black shapes), and ODBG-P-RVn (red shapes). Signal in infected cells treated with DMSO served as 100% fluorescence

intensity signal for reporter assays and 100% fluorescence-positive cell counts for image-based assays.

CPE inhibition was measured by determining cellular ATP levels using CellTiterGlo 2.0 assay reagent. ATP

levels in uninfected cells treated with DMSO served as 100% CPE inhibition. Dose-response curves were

fitted to the mean value of experiments performed in biological triplicate for each concentration in the

8-point, 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable

slope. Data points and error bars indicate the mean value and standard deviation of 3 biological

replicates; each colored shape/line in the legend represents an independent experiment performed in

biological triplicate.

Table 1. Mean antiviral activity of RVn, RDV, and ODBG-P-RVn in Vero E6, Huh7, and NCI-H358 cell lines

Virus Family	Virus	Species/Variant	Assay	Vero E6									Huh7/NCI-H358								
				RVn (GS-441524)			RDV (GS-5734)			ODBG-P-RVn			RVn (GS-441524)			RDV (GS-5734)			ODBG-P-RVn		
				EC ₅₀	EC ₉₀	SI (CC ₅₀ : >100)	EC ₅₀	EC ₉₀	SI (CC ₅₀ : >100)	EC ₅₀	EC ₉₀	SI (CC ₅₀ : >100)	EC ₅₀	EC ₉₀	SI (CC ₅₀ : >100)	EC ₅₀	EC ₉₀	SI (CC ₅₀ : 54.2 ± 6.0/ 77.2 ± 5.3)	EC ₅₀	EC ₉₀	SI (CC ₅₀ : 93.4 ± 3.0/ >100)
<i>Filoviridae</i>	EBOV	Rec. Makona-ZsG	REP	2.03 ± 0.50	7.54 ± 1.09	49	5.15 ± 1.09	17.31 ± 0.89	>19	0.39 ± 0.10	1.71 ± 0.25	>258	1.84 ± 0.31	6.91 ± 1.79	>54	0.020 ± 0.003	0.16 ± 0.02	2710	0.37 ± 0.06	2.13 ± 0.37	251
	MARV	Rec. Bat371-ZsG	REP	0.96 ± 0.09	4.05 ± 1.42	104	2.16 ± 0.27	10.22 ± 2.02	>46	0.19 ± 0.04	0.81 ± 0.12	>521	1.92 ± 0.06	4.47 ± 0.48	>52	0.025 ± 0.002	0.075 ± 0.003	2128	0.33 ± 0.02	0.99 ± 0.09	285
<i>Paramyxoviridae</i>	NIV-M	Rec. Malaysia-ZsG	REP	1.10 ± 0.40	2.20 ± 1.05	73	5.87 ± 0.19	9.82 ± 0.43	>16	0.31 ± 0.04	0.78 ± 0.28	>196	2.43 ± 0.31	5.95 ± 1.10	>41	0.075 ± 0.001	0.31 ± 0.04	1026	0.50 ± 0.06	2.83 ± 1.39	>198
	NIV-B	Bangladesh	CPE	0.48 ± 0.06	0.78 ± 0.19	207	3.34 ± 0.34	5.39 ± 0.29	>30	0.19 ± 0.01	0.30 ± 0.04	>522	ND	ND	N/A	ND	ND	N/A	ND	ND	N/A
	HeV	1996	CPE	0.52 ± 0.02	1.14 ± 0.02	192	2.84 ± 0.10	5.81 ± 0.44	>35	0.17 ± 0.01	0.38 ± 0.04	>599	3.42 ± 0.005	5.41 ± 0.29	>29	0.12 ± 0.0004	0.19 ± 0.01	661	0.82 ± 0.053	1.38 ± 0.05	>122
	HeV	1996	CPE	1.43 ± 0.17	12.06 ± 3.14	70	4.56 ± 0.20	17.58 ± 3.91	>22	0.37 ± 0.04	3.93 ± 1.98	>270	3.68 ± 0.08	6.33 ± 0.18	>27	0.16 ± 0.02	0.25 ± 0.03	491	0.95 ± 0.12	1.42 ± 0.03	>105
	MV	Rec. rMV ^{FL} -GFP(3)	REP	0.58 ± 0.20	1.71 ± 0.07	172	4.97 ± 0.25	6.12 ± 0.3	>20	0.16 ± 0.03	0.21 ± 0.01	>609	0.88 ± 0.16	6.99 ± 1.90	>113	0.025 ± 0.007	0.13 ± 0.09	3074	0.12 ± 0.003	0.86 ± 0.22	>803
	hPIV3	Rec. JS-GFP	FFU	0.14 ± 0.01	0.28 ± 0.02	70	0.43 ± 0.09	0.90 ± 0.03	>232	0.026 ± 0.002	0.050 ± 0.002	>3896	1.43 ± 0.16	1.98 ± 0.05	>70	0.031 ± 0.002	0.052 ± 0.01	2458	0.22 ± 0.01	0.43 ± 0.02	>457
	MuV	Rec. IA2006-eGFP	FFU	5.11 ± 0.20	7.80 ± 0.64	18	16.81 ± 1.23	25.1 ± 1.97	>4.9	1.13 ± 0.04	2.53 ± 0.25	>56	9.3 ± 0.30	13.71 ± 0.24	>11	0.20 ± 0.003	0.24 ± 0.003	266	1.85 ± 0.11	2.24 ± 0.23	50
<i>Pneumoviridae</i>	SoSuV	Rec. 2012-ZsG	REP	1.00 ± 0.10	2.72 ± 0.62	100	5.31 ± 1.8	19.10 ± 9.31	>19	0.31 ± 0.089	0.80 ± 0.06	>325	2.06 ± 0.09	7.76 ± 1.11	>48	0.052 ± 0.01	0.13 ± 0.02	1042	0.52 ± 0.10	1.08 ± 0.15	180
	RSV	Rec. rgRSV0224 (A2)	FFU	0.49 ± 0.05	0.62 ± 0.01	206	1.80 ± 0.08	2.40 ± 0.27	>55	0.10 ± 0.02	0.22 ± 0.03	>997	1.93 ± 0.02	2.36 ± 0.08	>51	0.078 ± 0.004	0.17 ± 0.02	991	0.55 ± 0.057	1.41 ± 0.09	>180
<i>Coronaviridae</i>	SARS-CoV-2	Rec. icSARS-CoV-2 mNG (WA1)	FFU	0.42 ± 0.09	0.60 ± 0.06	236	1.77 ± 0.13	2.81 ± 0.78	>56	0.10 ± 0.005	0.16 ± 0.01	>997	0.69 ± 0.01	1.50 ± 0.20	>144	0.011 ± 0.001	0.035 ± 0.002	5073	0.12 ± 0.02	0.69 ± 0.07	778
<i>Flaviviridae</i>	YFV	17D	CPE	3.52 ± 0.24	30.25 ± 10.08	28	19.86 ± 1.73	>50	>5	0.87 ± 0.043	7.37 ± 1.59	>114	36.83 ± 2.85	>50	>2.7	0.88 ± 0.057	3.09 ± 1.47	62	14.11 ± 0.90	>50	6.6
<i>Arenaviridae</i>	LASV	Rec. Josiah-ZsG	REP	NI	NI	N/A	NI	NI	N/A	31.14 ± 7.79	>50	>3	NI	NI	N/A	NI	NI	5.17 ± 0.33	19	NI	N/A
<i>Nairoviridae</i>	CCHF	Rec. IbAr10200-ZsG	REP	NI	NI	N/A	NI	NI	N/A	NI	NI	N/A	NI	NI	N/A	NI	NI	N/A	NI	NI	N/A

EC₅₀, 50% effective inhibition concentration; EC₉₀, 90% effective inhibition concentration; CC₅₀, 50% cytotoxic concentration; SI, selective index = EC₅₀/CC₅₀; REP, reporter; CPE, cytopathic effect; FFU, focus-forming unit; ND, not determined; NI, no inhibition; N/A, not applicable; Rec, recombinant. Mean values with ± standard deviation values were derived from 3 independent experiments performed in biological triplicates except for NIV-B (NCI-H358), HeV (NCI-H358), and YFV (Vero E6) which were performed twice in biological triplicates. Data in red text derived from Huh7 cells, data in blue derived from NCI-H358 cells. REP/FFU/CPE assays were conducted between 72-144 hpi. EC₅₀, EC₉₀, and CC₅₀ values were calculated using Graphpad Prism 9 software.

Table 2. Mean antiviral activity of RVn, RDV, and ODBG-P-RVn in primary-like hTERT-immortalized microvascular endothelial (TIME) and small airway epithelial (HSAEC1-KT) cell lines

Virus Family	Virus	Species/Variant	Assay	HSAEC1-KT									TIME								
				RVn (GS-441524)			RDV (GS-5734)			ODBG-P-RVn			RVn (GS-441524)			RDV (GS-5734)			ODBG-P-RVn		
				EC ₅₀	EC ₉₀	SI (CC ₅₀ : >100)	EC ₅₀	EC ₉₀	SI (CC ₅₀ : >100)	EC ₅₀	EC ₉₀	SI (CC ₅₀ : 20.5 ± 0.29)	EC ₅₀	EC ₉₀	SI (CC ₅₀ : >100)	EC ₅₀	EC ₉₀	SI (CC ₅₀ : 17.2 ± 0.42)	EC ₅₀	EC ₉₀	SI (CC ₅₀ : >50)
<i>Filoviridae</i>	EBOV	Rec. Makona-ZsG	REP	10.7 ± 2.62	21.79 ± 3.16	>9.3	0.17 ± 0.02	0.41 ± 0.14	>587	0.21 ± 0.02	1.06 ± 0.18	98	14.88 ± 0.28	17.24 ± 0.16	>3.36	0.13 ± 0.04	0.2 ± 0.01	132	0.99 ± 0.063	1.96 ± 0.043	>50
	MARV	Rec. Bat371-ZsG	VTR	ND	ND	N/A	0.11	0.82	>909	0.21	0.95	98	ND	ND	N/A	0.032	0.064	530	0.15	0.39	>324
<i>Paramyxoviridae</i>	NIV-M	Rec. Malaysia-ZsG	REP/FFU	35.53 ± 7.07	71.35 ± 1.28	>2.8	0.75 ± 0.19	2.92 ± 0.14	>133	0.71 ± 0.11	3.67 ± 0.49	29	5.2 ± 0.26	6.89 ± 0.86	>9.61	0.04 ± 0.003	0.086 ± 0.004	430	0.23 ± 0.036	0.66 ± 0.032	>213
	NIV-B	Bangladesh	CPE	16.46 ± 0.04	19.12 ± 0.05	>6.1	0.23 ± 0.01	0.31 ± 0.06	>440	0.57 ± 0.013	0.97 ± 0.21	36	13.53 ± 2.44	17.52 ± 0.77	>3.70	0.10 ± 0.01	0.20 ± 0.01	172	0.75 ± 0.05	2.01 ± 0.30	>66
	HeV	1994	VTR	16.12 ± 4.21	78.1 ± 35.08	>6.2	0.31 ± 0.04	0.075 ± 0.004	>318	0.90 ± 0.07	10.22 ± 4.99	23	ND	ND	N/A	0.054	0.07	319	0.26	0.77	>195
	HeV	1994	CPE	11.23 ± 0.63	33.6 ± 1.58	>8.9	0.21 ± 0.063	0.62 ± 0.20	>379	0.41 ± 0.039	1.71 ± 0.66	50									
	MV	Rec. rMV ^{FL} -GFP(3)	CPE	11.52 ± 1.49	26.11 ± 4.44	>8.7	0.22 ± 0.04	0.65 ± 0.11	>463	0.42 ± 0.023	1.19 ± 0.061	49									
	hPIV3	Rec. JS-GFP	REP	4.98 ± 0.37	12.02 ± 2.7	>20	0.063 ± 0.02	0.128 ± 0.016	>1587	0.082 ± 0.026	0.29 ± 0.043	251									
	hPIV3	Rec. JS-GFP	FFU	4.96 ± 0.05	5.77 ± 0.06	>20	0.063 ± 0.001	0.074 ± 0.002	>1582	0.091 ± 0.009	0.20 ± 0.008	226									
<i>Pneumoviridae</i>	RSV	Rec. rgRSV0224 (A2)	FFU	4.92 ± 0.47	8.09 ± 0.68	>20	0.088 ± 0.026	0.21 ± 0.033	>1134	0.12 ± 0.008	0.34 ± 0.047	176									

EC₅₀, 50% effective inhibition concentration; EC₉₀, 90% effective inhibition concentration; CC₅₀, 50% cytotoxic concentration; SI, selective index = EC₅₀/CC₅₀; REP, reporter; CPE, cytopathic effect; FFU, focus-forming unit; VTR, virus titer reduction; ND, not determined; N/A, not applicable; Rec, recombinant. Mean values with ± standard deviation values were derived from a minimum of 3 independent experiments performed in biological triplicates. REP/FFU/CPE/VTR assays were conducted at 72 hpi. EC₅₀, EC₉₀, and CC₅₀ values were calculated using Graphpad Prism 9 software.

Figure 1. Comparison of antiviral activities of RVn, RDV, and ODBG-P-RVn in African green monkey (Vero E6), Human hepatoma (Huh7), and human bronchioalveolar carcinoma (NCI-H358) cell lines using reporter-based, image-based, and cytopathic effect assays. Representative dose response inhibition of virus replication and induction of cell cytotoxicity in by RVn (blue shapes), RDV (black shapes), and ODBG-P-RVn (red shapes). A) Direct measurement of green fluorescence reporter intensity by recombinant EBOV expressing ZsGreen protein in Vero E6 (left panel) and Huh7 (middle panel) cells, and recombinant NiV expressing ZsGreen protein in NCI-H358 (right panel) cells. B) Image-based counting of reporter fluorescence-positive cells infected with recombinant SARS-CoV-2 expressing mNeonGreen protein (Vero E6 and Huh7) and recombinant RSV expressing eGFP (NCI-H358). Infected cells treated with DMSO represented 100% fluorescence intensity signal and 100% fluorescence-positive cell counts. C) Inhibition of cytopathic effect (CPE) by YFV (Vero E6 and Huh7) and HeV (NCI-H358) measured by levels of cellular ATP (CellTiterGlo 2.0). Uninfected cells treated with DMSO served as 100% CPE inhibition. D) Compound cytotoxicity/cell viability measured by CellTiterGlo 2.0 assay. Dose response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 biological replicates; each colored shape/line in the legend represents an independent experiment performed in biological triplicate.

Figure 2. Comparison of cell-type dependent antiviral activities of RVn, RDV, and ODBG-P-RVn in primary-like hTERT-immortalized microvascular endothelial (TIME) and small airway epithelial cells (HSAEC1-KT). A) Representative dose response inhibition of recombinant EBOV, NiV, and MARV expressing ZsGreen protein in TIME cells. B) Infectious yield reduction by RDV and ODBG-P-RVn against EBOV-ZsG (left panel) and NiV-ZsG (middle panel). Compound cytotoxicity/cell viability (right panel) in TIME cells measured by CellTiterGlo 2.0 assay. C) Representative dose response inhibition of recombinant EBOV, NiV, and MARV expressing ZsGreen protein in HSAEC1-KT cells. (D) Infectious yield reduction by RDV and ODBG-P-RVn against EBOV-ZsG (left panel) and NiV-ZsG (middle panel) in HSAEC1-KT cells. Compound cytotoxicity/cell viability (right panel) in HSAEC1-KT cells measured by CellTiterGlo 2.0 assay. Dose response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 or 4 biological replicates; each colored shape/line in the legend represents an independent experiment performed in biological triplicate. Infectious yield reduction assays were conducted once with biological quadruplicates.

Supplemental Figure S1. Comparison of antiviral activities of RVn, RDV, and ODBG-P-RVn in African green monkey (Vero E6) cells using reporter-based, image-based, and cytopathic effect assays. Representative dose response inhibition of virus replication by RVn (blue shapes), RDV (black shapes), and ODBG-P-RVn (red shapes). Infected cells treated with DMSO served as 100% fluorescence intensity signal for reporter assays and 100% fluorescence-positive cell counts for image-based assays. Inhibition of cytopathic effect was measured by levels of cellular ATP using CellTiterGlo 2.0 assay reagent (Promega, WI). Uninfected cells treated with DMSO served as 100% CPE inhibition. Dose response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 biological replicates; each colored shape/line in the legend represents an independent experiment performed in 3 biological replicates. This article is a US Government work and, as such, is in the public domain in the United States of America. bioRxiv preprint doi: <https://doi.org/10.1101/2021.08.06.455494>; this version posted August 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. This article is a US Government work and, as such, is in the public domain in the United States of America.

Supplemental Figure S2. Comparison of antiviral activities of RVn, RDV, and ODBG-P-RVn in human hepatoma (Huh7) cells using reporter-based, image-based, and cytopathic effect assays. Representative dose response inhibition of virus replication by RVn (blue shapes), RDV (black shapes), and ODBG-P-RVn (red shapes). Infected cells treated with DMSO served as 100% fluorescence intensity signal for reporter assays and 100% fluorescence-positive cell counts for image-based assays. Inhibition of cytopathic effect was measured by levels of cellular ATP using CellTiterGlo 2.0 assay reagent (Promega, WI). Uninfected cells treated with DMSO served as 100% CPE inhibition. Dose response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 biological replicates; each colored shape/line in the legend represents an independent experiment performed in biological triplicate.

Supplemental Figure S3. Comparison of antiviral activities of RVn, RDV, and ODBG-P-RVn in human bronchioalveolar carcinoma (NCI-H358) cells using reporter-based, image-based, and cytopathic effect assays. Representative dose response inhibition of virus replication by RVn (blue shapes), RDV (black shapes), and ODBG-P-RVn (red shapes). Infected cells treated with DMSO served as 100% fluorescence intensity signal for reporter assays and 100% fluorescence-positive cell counts for image-based assays. Inhibition of cytopathic effect was measured by levels of cellular ATP using CellTiterGlo 2.0 assay reagent (Promega, WI). Uninfected cells treated with DMSO served as 100% CPE inhibition. Dose response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 biological replicates; each colored shape/line in the legend represents an independent experiment performed in biological triplicate.

Supplemental Figure S4. Comparison of antiviral activities of RVn, RDV, and ODBG-P-RVn in primary-like human small airway epithelial (HSAEC1-KT) cells using reporter-based, image-based, and cytopathic effect assays. Representative dose response inhibition of virus replication by RVn (blue shapes), RDV (black shapes), and ODBG-P-RVn (red shapes). Infected cells treated with DMSO served as 100% fluorescence intensity signal for reporter assays and 100% fluorescence-positive cell counts for image-based assays. Inhibition of cytopathic effect was measured by levels of cellular ATP using CellTiterGlo 2.0 assay reagent (Promega, WI). Uninfected cells treated with DMSO served as 100% CPE inhibition. Dose response curves were fitted to the mean value of experiments performed in biological triplicate for each concentration in the 8-point 3-fold dilution series using a 4-parameter non-linear logistic regression curve with variable slope. Data points and error bars indicate the mean value and standard deviation of 3 biological replicates; each colored shape/line in the legend represents an independent experiment